GENETIC TESTING MARKET ANALYSIS

Leading Companies

Global Genetic Testing Market: Key Developments

In July 2022, 1health.io Inc. and Apollo Health Group collaborated to bring Apollo’s specialized high performing NGS tests, such as hereditary cancer genetic screenings and pharmacogenetics screenings to the broader clinical market.

In April 2022, MedGenome Labs announced the development and launch of an AI-enabled variant interpretation software suite, called VarMiner. It will help clinicians, molecular geneticists, and/or Genome analysts to interpret and report actionable genetic variants.

In April 2022, Invitae launched Neurodevelopmental Disorders (NDD) package to deliver a robust testing suite that can deliver actionable genetic insights to inform treatment plans for children with developmental disabilities.

In January 2022, Genetic Analysis AS and Thalys Medical Technology Group Corporation entered into a Laboratory Developed Test (LDT) agreement to evaluate and develop innovative diagnostic solutions for the rapidly growing human microbiota market in China.

Global Genetic Testing Market: Key Companies Insights

The global genetic testing market is highly competitive. This is attributed to the rise in burden of genetic and rare disorders, as a result, players in the market are focusing on developing/launching novel products in the market.

Some of the key players in the global genetic testing market are 23&Me Inc., Qiagen NV, Eurofins Scientific, PerkinElmer Inc., Illumina Inc., Danaher Corporation, Myriad Genetics Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd., Quest Diagnostics Incorporated, BioRad Laboratories Inc., and DiaSorin S.p.A. (Luminex Corporation), among others.